|
Download validation_report.md from xpertsystems/hconc005-sample: direct link, hf CLI and curl.
- Browser
- Download file 4.96 kB
-
https://huggingface.co/datasets/xpertsystems/hconc005-sample/resolve/main/validation_report.md
- Command line
-
hf download hf://datasets/xpertsystems/hconc005-sample/validation_report.md
-
curl -L -o validation_report.md https://huggingface.co/datasets/xpertsystems/hconc005-sample/resolve/main/validation_report.md
4.96 kB
HC-ONC-005 — Pancreatic Cancer (PDAC)
Validation Report
- Generated: 2026-05-26T21:18:53.369921+00:00
- N patients: 500 (primary) + ~4,400 CA 19-9 panel rows + ~100 surgical rows + 500 molecular rows + ~860 treatment-history rows
- Seed: 42
- Weighted Score: 10.0/10
- Grade: A+
Scorecard
| Metric | Value | Target | Score | Status | Source |
|---|---|---|---|---|---|
age_mean |
70.704 | [66.0, 75.0] | 10.0 | PASS | SEER PDAC median age 70-71 |
female_pct |
45.8 | [38.0, 52.0] | 10.0 | PASS | SEER PDAC female ~45-48% |
diabetes_pct |
41.2 | [28.0, 48.0] | 10.0 | PASS | PDAC enriched in diabetes ~30-40% (Aggarwal 2013, Mizrahi 2020) |
stage_iv_pct |
47.0 | [38.0, 58.0] | 10.0 | PASS | SEER PDAC Stage IV at-dx ~50-55% |
stage_i_pct |
5.2 | [2.0, 9.0] | 10.0 | PASS | SEER PDAC Stage I at-dx ~5% (most present advanced) |
head_tumor_pct |
71.4 | [60.0, 80.0] | 10.0 | PASS | PDAC: pancreatic head ~65-75% (Hidalgo 2010) |
jaundice_in_head_pct |
64.986 | [60.0, 80.0] | 10.0 | PASS | Head PDAC presents with obstructive jaundice ~70-80% |
kras_mutation_pct |
93.6 | ≥90.0 | 10.0 | PASS | TCGA PAAD KRAS mutation ~93%, FLOOR (PDAC hallmark) |
kras_g12d_pct |
30.4 | [28.0, 42.0] | 10.0 | PASS | TCGA PAAD KRAS G12D ~36% (most common variant) |
kras_g12v_pct |
24.6 | [15.0, 28.0] | 10.0 | PASS | TCGA PAAD KRAS G12V ~22% |
kras_variants_exclusive_pct |
100.0 | ≥100.0 | 10.0 | PASS | Structural: KRAS variants categorical (exactly one per patient), FLOOR |
tp53_mutation_pct |
73.2 | [65.0, 82.0] | 10.0 | PASS | TCGA PAAD TP53 mutation ~70-75% |
smad4_lost_pct |
48.2 | [38.0, 55.0] | 10.0 | PASS | TCGA PAAD SMAD4 loss ~50% (Iacobuzio-Donahue 2009) |
cdkn2a_lost_pct |
63.2 | [52.0, 68.0] | 10.0 | PASS | TCGA PAAD CDKN2A loss ~60% |
brca2_germline_pct |
2.8 | [1.5, 8.0] | 10.0 | PASS | POLO PDAC trial: BRCA2 germline |
brca1_germline_pct |
2.2 | [0.5, 4.0] | 10.0 | PASS | PDAC BRCA1 germline ~1-2% |
parp_eligible_pct |
9.2 | [6.0, 18.0] | 10.0 | PASS | PDAC HRR/DDR composite (BRCA1/2, PALB2, ATM) ~10-15% |
msi_h_pct |
0.8 | [0.1, 4.0] | 10.0 | PASS | PDAC MSI-H rare ~1% (Hu 2018; KEYNOTE-158 enrolled <1%) |
surgery_rate_pct |
20.6 | [12.0, 30.0] | 10.0 | PASS | PDAC overall surgical resection rate ~15-20% (cohort-driven by Stage IV) |
whipple_in_head_surgical_pct |
88.571 | ≥80.0 | 10.0 | PASS | Head PDAC undergoing surgery → Whipple/PPPD ~85-95%, FLOOR |
r0_resection_pct |
72.816 | [60.0, 85.0] | 10.0 | PASS | Modern PDAC R0 ~65-75% (Strobel 2017) |
fistula_bc_pct |
25.243 | [15.0, 32.0] | 10.0 | PASS | ISGPF Grade B/C fistula ~20-25% |
dge_bc_pct |
20.388 | [12.0, 32.0] | 10.0 | PASS | ISGPS DGE Grade B/C ~15-25% |
folfirinox_in_palliative_pct |
38.631 | [25.0, 50.0] | 10.0 | PASS | PRODIGE-4 era FOLFIRINOX uptake in fit patients ~30-40% |
gem_nabp_in_palliative_pct |
43.046 | [35.0, 55.0] | 10.0 | PASS | MPACT era Gem+NabP uptake ~40-50% |
pembrolizumab_in_msi_h_pct |
75.0 | ≥40.0 | 10.0 | PASS | KEYNOTE-158: Pembro for MSI-H PDAC, FLOOR (high variance at small n) |
olaparib_in_parp_eligible_pct |
28.261 | [15.0, 50.0] | 10.0 | PASS | POLO era olaparib maintenance in HRR+ PDAC ~25-40% real-world |
os_median_overall_mo |
5.75 | [4.5, 9.0] | 10.0 | PASS | PDAC overall median OS ~6-11mo; cohort heavily Stage IV-enriched |
os_median_stage4_mo |
5.25 | [3.5, 8.0] | 10.0 | PASS | PDAC Stage IV median OS ~6-8mo (PRODIGE-4, MPACT) |
pfs_median_mo |
2.385 | [1.5, 4.0] | 10.0 | PASS | PDAC mPDAC PFS ~3-6mo (regimen-dependent) |
orr_pct |
22.6 | [15.0, 35.0] | 10.0 | PASS | PDAC palliative ORR ~20-30% (NAPOLI-3 ~42%, MPACT ~23%) |
ctdna_in_stage4_pct |
89.362 | [70.0, 95.0] | 10.0 | PASS | PDAC ctDNA detection in advanced ~80-90% (Cohen 2018, Bachet 2020) |
liver_mets_in_stage4_pct |
48.936 | [40.0, 65.0] | 10.0 | PASS | PDAC Stage IV liver mets ~50% (Yachida 2010) |
stage_resectability_monotonic_pct |
100.0 | ≥100.0 | 10.0 | PASS | Structural: Stage I→Resectable, Stage IV→Metastatic ordering preserved, FLOOR |
ca19_9_panel_median_visits_per_pt |
6.0 | [4.0, 12.0] | 10.0 | PASS | CA 19-9 longitudinal: variable visits per patient (depends on OS); median 6-7 |
Notes
- Floor metrics (
kras_mutation_pct,whipple_in_head_surgical_pct,kras_variants_exclusive_pct,pembrolizumab_in_msi_h_pct,stage_resectability_monotonic_pct) are one-sided ≥ threshold checks. - Five-table output: primary cohort + CA 19-9 longitudinal panel + surgical-cohort subset + molecular panel + treatment history. All tables join on
patient_id. - Patched generator: the original generator had a fatal
rng.integers(0, 2**128)overflow at line 60 (numpy max int64). The wrapper applies a minimal in-place patch composing a 128-bit UUID from four 32-bit draws. SeeREADME.mdfor full disclosure.